STOCK TITAN

Benitec Biopharma to Participate in Upcoming Conferences in March

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences

Benitec Biopharma (NASDAQ: BNTC), a clinical-stage biotechnology company specializing in gene therapy and 'Silence and Replace' DNA-directed RNA interference (ddRNAi) platform, has announced its participation in three major healthcare conferences in March 2025.

The company will present at:

  • TD Cowen 45th Annual Health Care Conference on March 5, 2025 (9:50-10:20 AM EST)
  • Leerink Partners Global Healthcare Conference on March 12, 2025 (9:20-9:50 AM EST)
  • 2025 Muscular Dystrophy Association Clinical & Scientific Conference in Dallas, TX, featuring two sessions on March 18-19, 2025, focusing on Oculopharyngeal Muscular Dystrophy and Clinical Trial Updates

All presentations will be available via live webcast, and one-on-one meetings can be scheduled with management.

Benitec Biopharma (NASDAQ: BNTC), un'azienda biotecnologica in fase clinica specializzata nella terapia genica e nella piattaforma di interferenza RNA diretta da DNA 'Silence and Replace' (ddRNAi), ha annunciato la sua partecipazione a tre importanti conferenze sanitarie a marzo 2025.

L'azienda presenterà a:

  • TD Cowen 45ª Conferenza Annuale sulla Salute il 5 marzo 2025 (9:50-10:20 AM EST)
  • Conferenza Globale sulla Salute di Leerink Partners il 12 marzo 2025 (9:20-9:50 AM EST)
  • Conferenza Clinica e Scientifica 2025 dell'Associazione Distrofia Muscolare a Dallas, TX, con due sessioni il 18-19 marzo 2025, incentrate sulla Distrofia Muscolare Oculofaringea e sugli Aggiornamenti delle Sperimentazioni Cliniche

Tutte le presentazioni saranno disponibili tramite webcast in diretta e sarà possibile programmare incontri individuali con il management.

Benitec Biopharma (NASDAQ: BNTC), una empresa biotecnológica en etapa clínica especializada en terapia génica y la plataforma de interferencia de ARN dirigida por ADN 'Silence and Replace' (ddRNAi), ha anunciado su participación en tres importantes conferencias de salud en marzo de 2025.

La empresa presentará en:

  • 45ª Conferencia Anual de Salud de TD Cowen el 5 de marzo de 2025 (9:50-10:20 AM EST)
  • Conferencia Global de Salud de Leerink Partners el 12 de marzo de 2025 (9:20-9:50 AM EST)
  • Conferencia Clínica y Científica 2025 de la Asociación de Distrofia Muscular en Dallas, TX, con dos sesiones el 18-19 de marzo de 2025, centrándose en la Distrofia Muscular Oculofaringea y Actualizaciones de Ensayos Clínicos

Todas las presentaciones estarán disponibles a través de una transmisión en vivo, y se pueden programar reuniones uno a uno con la dirección.

Benitec Biopharma (NASDAQ: BNTC)는 유전자 치료와 'Silence and Replace' DNA 지향 RNA 간섭(ddRNAi) 플랫폼을 전문으로 하는 임상 단계의 생명공학 회사로, 2025년 3월에 열리는 세 가지 주요 의료 회의에 참여한다고 발표했습니다.

회사는 다음과 같은 회의에서 발표할 예정입니다:

  • TD Cowen 제45회 연례 의료 회의 2025년 3월 5일 (오전 9:50-10:20 EST)
  • Leerink Partners 글로벌 의료 회의 2025년 3월 12일 (오전 9:20-9:50 EST)
  • 2025 근육 위축 협회 임상 및 과학 회의 텍사스주 댈러스에서 2025년 3월 18-19일에 두 세션이 열리며, 안구인두 근육 위축 및 임상 시험 업데이트에 중점을 둡니다.

모든 발표는 라이브 웹캐스트를 통해 제공되며, 경영진과의 일대일 회의를 예약할 수 있습니다.

Benitec Biopharma (NASDAQ: BNTC), une entreprise de biotechnologie en phase clinique spécialisée dans la thérapie génique et la plateforme d'interférence ARN dirigée par ADN 'Silence and Replace' (ddRNAi), a annoncé sa participation à trois grandes conférences sur la santé en mars 2025.

L'entreprise présentera lors des événements suivants :

  • 45ème Conférence Annuelle sur la Santé de TD Cowen le 5 mars 2025 (9h50-10h20 EST)
  • Conférence Mondiale sur la Santé de Leerink Partners le 12 mars 2025 (9h20-9h50 EST)
  • Conférence Clinique et Scientifique 2025 de l'Association de Dystrophie Musculaire à Dallas, TX, avec deux sessions les 18 et 19 mars 2025, axées sur la Dystrophie Musculaire Oculopharyngée et les Mises à Jour des Essais Cliniques

Toutes les présentations seront disponibles via un webinaire en direct, et des réunions individuelles peuvent être planifiées avec la direction.

Benitec Biopharma (NASDAQ: BNTC), ein biopharmazeutisches Unternehmen in der klinischen Phase, das sich auf Gentherapie und die 'Silence and Replace' DNA-gesteuerte RNA-Interferenz (ddRNAi) Plattform spezialisiert hat, hat seine Teilnahme an drei wichtigen Gesundheitskonferenzen im März 2025 angekündigt.

Das Unternehmen wird auf folgenden Veranstaltungen präsentieren:

  • 45. TD Cowen Jahreskonferenz für Gesundheitswesen am 5. März 2025 (9:50-10:20 Uhr EST)
  • Leerink Partners Globale Gesundheitskonferenz am 12. März 2025 (9:20-9:50 Uhr EST)
  • 2025 Konferenz für klinische und wissenschaftliche Forschung der Muskulären Dystrophie Vereinigung in Dallas, TX, mit zwei Sitzungen am 18.-19. März 2025, die sich auf oculopharyngeale Muskeldystrophie und Aktualisierungen klinischer Studien konzentrieren

Alle Präsentationen werden über einen Live-Webcast verfügbar sein, und es können Einzelgespräche mit der Geschäftsleitung vereinbart werden.

Positive
  • None.
Negative
  • None.

HAYWARD, Calif., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ: BNTC) (“Benitec” or the “Company”), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary “Silence and Replace” DNA-directed RNA interference ("ddRNAi") platform, today announced that its management team will participate in the following upcoming conferences.

TD Cowen 45th Annual Health Care Conference
Date: March 5, 2025
Time of Presentation: 9:50 AM to 10:20 AM EST
Format: Presentation & 1x1 Meetings

The Benitec presentation will also be available via live webcast here.

Leerink Partners Global Healthcare Conference 2025
Date: March 12, 2025
Time of Presentation: 9:20 AM to 9:50 AM EST
Format: Fireside Chat & 1x1 Meetings

The Benitec presentation will also be available via live webcast here.

2025 Muscular Dystrophy Association Clinical & Scientific Conference
Session: Pre-clinical and Clinical Efforts in Oculopharyngeal Muscular Dystrophy
Date & Time of Panel Discussion: March 18th, 2025 from 11:00 AM to 12:00 PM CST
Location: Dallas, TX

Session: Clinical Trial Updates, Late-Breaking Oral Abstracts
Date & Time of Presentation: March 19th, 2025 from 1:15 PM to 1:30 PM CST
Location: Dallas, TX

Please contact your conference representative to schedule a 1x1 meeting with Benitec management.

About Benitec Biopharma Inc.
Benitec Biopharma Inc. (“Benitec” or the “Company”) is a clinical-stage biotechnology company focused on the advancement of novel genetic medicines with headquarters in Hayward, California. The proprietary “Silence and Replace” DNA-directed RNA interference platform combines RNA interference, or RNAi, with gene therapy to create medicines that simultaneously facilitate sustained silencing of disease-causing genes and concomitant delivery of wildtype replacement genes following a single administration of the therapeutic construct. The Company is developing Silence and Replace-based therapeutics for chronic and life-threatening human conditions including Oculopharyngeal Muscular Dystrophy (OPMD). A comprehensive overview of the Company can be found on Benitec’s website at www.benitec.com.

Investor Relations Contact:

Irina Koffler
LifeSci Advisors
Tel: (917) 734-7387
ikoffler@lifesciadvisors.com


FAQ

What conferences will Benitec Biopharma (BNTC) attend in March 2025?

BNTC will attend TD Cowen Healthcare Conference (March 5), Leerink Partners Global Healthcare Conference (March 12), and the Muscular Dystrophy Association Conference (March 18-19) in Dallas.

What will BNTC present at the 2025 Muscular Dystrophy Association Conference?

BNTC will participate in sessions about Oculopharyngeal Muscular Dystrophy and present Clinical Trial Updates in Late-Breaking Oral Abstracts.

How can investors access Benitec's (BNTC) conference presentations in March 2025?

Investors can access BNTC's presentations via live webcasts for both the TD Cowen and Leerink Partners conferences.

What is Benitec Biopharma's (BNTC) main technology platform?

BNTC specializes in the 'Silence and Replace' DNA-directed RNA interference (ddRNAi) platform for developing novel genetic medicines.

When will BNTC present at the Leerink Partners Global Healthcare Conference 2025?

BNTC will present on March 12, 2025, from 9:20 AM to 9:50 AM EST in a Fireside Chat format.

Benitec Biopharm

NASDAQ:BNTC

BNTC Rankings

BNTC Latest News

BNTC Stock Data

295.11M
22.58M
4.39%
82.59%
0.29%
Biotechnology
Pharmaceutical Preparations
Link
United States
HAYWARD